AHA-1 stimulates the inherent ATPase activity of yeast and human HSP 90 and interacts with the cytoplasmic tail of vesticular stomatitis virus glycoprotein. AHA-1 regulates HSP 90 by influencing the conformational state of the "ATP lid" and consequent N-terminal dimerization. It is crucial for cell viability under non-optimal growth conditions when HSP 90 levels are limiting. AHA-1 is a cytosolic protein and may transiently interact with the endoplasmic reticulum. It can have an affect on one step in the endoplasmic to Golgi trafficking. AHA-1 is expressed in numerous tissues, including brain, heart, skeletal muscle and kidney and, at lower levels, in liver and placenta. It is induced by heat shock and treatment with the HSP 90 inhibitor 17-demeth-oxygeldanamycin.
AHA-1 Polyclonal Antibody detects endogenous levels of AHA-1 protein.
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB: 1:500-1:2000, IHC-p: 1:100-1:300, ELISA: 1:20000. Not yet tested in other applications.
AHA-1 Polyclonal Antibody product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.
Find more details at http://www.abbkine.com/product/aha-1-polyclonal-antibody-abp50613.
bio-equip.cn